DUBLIN, Ohio--(BUSINESS WIRE)--
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) announces a conference call on Thursday, May 5, 2016 at 4:30 p.m. ET to further update the market on its Manocept™ macrophage targeting programs for immunodiagnostic and immunotherapeutic applications.
As mentioned on our previous call, we are eager to keep an open channel of discussion with investors regarding the important developments with the Manocept technology. We will devote a substantial portion of the call to Q&A as we want to make certain we address the subjects that are important to investors. We plan to continue discussing the progress of this promising technology during regularly scheduled Macrophage Therapeutics update calls.
Conference Call Details
Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website,
|Event:||Navidea and Macrophage Therapeutics Manocept™ Program Update Call|
|Date/Time:||Thursday, May 5, 2016 at 4:30 p.m. ET|
|Dial-in Number – US:||(855) 897-5884|
|Dial in Number – Int’l:||(720) 634-2940|
A webcast replay will be available on the Investor Relations section of our website at
About Manocept CD206 Immunotargeting Platform for Therapeutics Development
Manocept™ CD206 Immunotargeting Platform is a proprietary mannose-containing...